Xequel Bio selects Societal CDMO to support clinical development of iNexin

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Clinical development Manufacturing Patent

Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

The agreement spans a range of Societal CDMO’s offerings including process development and clinical trial services​, culminating in Current Good Manufacturing Practice (cGMP) of the compound and placebo for upcoming phase 2 clinical trials of iNexin.

iNexin is a sterile, preservative-free ophthalmic solution containing aCT1 peptide that is currently being evaluated by Xequel for the potential treatment of persistent corneal epithelial defects (PCED).

“We are pleased to have been selected by Xequel to continue our support of this important investigational drug candidate in the ophthalmology space,” said David Enloe, chief executive officer of Societal CDMO.

“It is gratifying to be able to grow this relationship in lockstep with the advancement of iNexin into the next phase of its clinical development, demonstrating our ability to meet the evolving needs of our customers as they mature their development pipelines.”

This new agreement is the latest highlight in what has been an active period for Societal CDMO’s business development, project management and operations teams, Enloe said.

“In just the past six weeks, we have announced new customer agreements with Longboard Pharmaceuticals and Xequel, project expansion agreements with several existing customers, and an approval from FDA for manufacturing of a commercial tablet at our Georgia facility,” he added.

“We continue to deliver against our growth strategy and look forward to maintaining the momentum as we move through 2023.”

Related news

Show more

Follow us


View more